Peking University Third Hospital
Beijing, Beijing Municipality, 100083, China
NCT Number: NCT06501586
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) effects of SGB-3908 in healthy subjects and mildly hypertensive subjects. The study will be a single ascending dose (SAD) phase.
Looking for future studies?
Notify Me18 year–55 year
All sexes
Interventional
Phase 1
Beijing, Beijing Municipality, 100083, China
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
SGB-3908 for sc injection
Normal saline (0.9% NaCl) matching volume of SGB-3908 doses will be administered
Time frame: up to approximately 12 months
Time frame: up to approximately 12 months
Time frame: Up to Day 3
Time frame: Up to Day 3
Time frame: up to approximately 6 months
Suzhou Sanegene Bio Inc.
Industry
A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Characteristics of SGB-3908 After a Single Administration in Healthy Subjects and Mildly Hypertensive Subjects
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06461273
Behavior, Body Weight
Newark, New Jersey, United States
View Trial DetailsNCT05086523
Cardiovascular Diseases, Essential Hypertension
Prague, Czechia
View Trial DetailsNCT03480217
Cardiovascular Diseases, Essential Hypertension
New York, United States
View Trial DetailsNCT03503773
Cardiovascular Diseases, Essential Hypertension
Brussels, Belgium
View Trial Details